The global Nonalcoholic Steatohepatitis (NASH) market size was estimated at USD 3064.20 million in 2024 and is projected to reach USD 96424.66 million by 2032, exhibiting a CAGR of 46.70% during the forecast period.
North America Nonalcoholic Steatohepatitis (NASH) market size was estimated at USD 1565.59 million in 2024, at a CAGR of 40.03% during the forecast period of 2025 through 2032.
Report Overview
Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
This report provides a deep insight into the global Nonalcoholic Steatohepatitis (NASH) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Nonalcoholic Steatohepatitis (NASH) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nonalcoholic Steatohepatitis (NASH) market in any manner.
Global Nonalcoholic Steatohepatitis (NASH) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- AstraZeneca
- Arena Pharmaceuticals
- GSK
- Novo Nordisk
- Roche
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
Market Segmentation (by Type)
- Obeticholic acid?OCA?
- Selonsertib
Market Segmentation (by Application)
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Nonalcoholic Steatohepatitis (NASH) Market
- Overview of the regional outlook of the Nonalcoholic Steatohepatitis (NASH) Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Nonalcoholic Steatohepatitis (NASH)
1.2 Key Market Segments
1.2.1 Nonalcoholic Steatohepatitis (NASH) Segment by Type
1.2.2 Nonalcoholic Steatohepatitis (NASH) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Nonalcoholic Steatohepatitis (NASH) Market Overview
2.1 Global Market Overview
2.1.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Nonalcoholic Steatohepatitis (NASH) Market Competitive Landscape
3.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Manufacturers (2019-2025)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2019-2025)
3.3 Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Nonalcoholic Steatohepatitis (NASH) Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Nonalcoholic Steatohepatitis (NASH) Sales Sites, Area Served, Product Type
3.6 Nonalcoholic Steatohepatitis (NASH) Market Competitive Situation and Trends
3.6.1 Nonalcoholic Steatohepatitis (NASH) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Nonalcoholic Steatohepatitis (NASH) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Nonalcoholic Steatohepatitis (NASH) Industry Chain Analysis
4.1 Nonalcoholic Steatohepatitis (NASH) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Nonalcoholic Steatohepatitis (NASH) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Nonalcoholic Steatohepatitis (NASH) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2019-2025)
6.3 Global Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2019-2025)
6.4 Global Nonalcoholic Steatohepatitis (NASH) Price by Type (2019-2025)
7 Nonalcoholic Steatohepatitis (NASH) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Nonalcoholic Steatohepatitis (NASH) Market Sales by Application (2019-2025)
7.3 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2019-2025)
7.4 Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2019-2025)
8 Nonalcoholic Steatohepatitis (NASH) Market Consumption by Region
8.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.1.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.1.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region
8.2 North America
8.2.1 North America Nonalcoholic Steatohepatitis (NASH) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Nonalcoholic Steatohepatitis (NASH) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Nonalcoholic Steatohepatitis (NASH) Market Production by Region
9.1 Global Production of Nonalcoholic Steatohepatitis (NASH) by Region (2019-2025)
9.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2019-2025)
9.3 Global Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Nonalcoholic Steatohepatitis (NASH) Production
9.4.1 North America Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2019-2025)
9.4.2 North America Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Nonalcoholic Steatohepatitis (NASH) Production
9.5.1 Europe Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2019-2025)
9.5.2 Europe Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Nonalcoholic Steatohepatitis (NASH) Production (2019-2025)
9.6.1 Japan Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2019-2025)
9.6.2 Japan Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Nonalcoholic Steatohepatitis (NASH) Production (2019-2025)
9.7.1 China Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2019-2025)
9.7.2 China Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 AstraZeneca
10.1.1 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Basic Information
10.1.2 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Overview
10.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.1.4 AstraZeneca Business Overview
10.1.5 AstraZeneca Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
10.1.6 AstraZeneca Recent Developments
10.2 Arena Pharmaceuticals
10.2.1 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
10.2.2 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
10.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.2.4 Arena Pharmaceuticals Business Overview
10.2.5 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
10.2.6 Arena Pharmaceuticals Recent Developments
10.3 GSK
10.3.1 GSK Nonalcoholic Steatohepatitis (NASH) Basic Information
10.3.2 GSK Nonalcoholic Steatohepatitis (NASH) Product Overview
10.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.3.4 GSK Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
10.3.5 GSK Business Overview
10.3.6 GSK Recent Developments
10.4 Novo Nordisk
10.4.1 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Basic Information
10.4.2 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Overview
10.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.4.4 Novo Nordisk Business Overview
10.4.5 Novo Nordisk Recent Developments
10.5 Roche
10.5.1 Roche Nonalcoholic Steatohepatitis (NASH) Basic Information
10.5.2 Roche Nonalcoholic Steatohepatitis (NASH) Product Overview
10.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.5.4 Roche Business Overview
10.5.5 Roche Recent Developments
10.6 Vivus
10.6.1 Vivus Nonalcoholic Steatohepatitis (NASH) Basic Information
10.6.2 Vivus Nonalcoholic Steatohepatitis (NASH) Product Overview
10.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.6.4 Vivus Business Overview
10.6.5 Vivus Recent Developments
10.7 Arisaph Pharmaceuticals
10.7.1 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
10.7.2 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
10.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.7.4 Arisaph Pharmaceuticals Business Overview
10.7.5 Arisaph Pharmaceuticals Recent Developments
10.8 Cempra Pharmaceuticals
10.8.1 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
10.8.2 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
10.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.8.4 Cempra Pharmaceuticals Business Overview
10.8.5 Cempra Pharmaceuticals Recent Developments
10.9 Galectin Therapeutics
10.9.1 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Basic Information
10.9.2 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Overview
10.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.9.4 Galectin Therapeutics Business Overview
10.9.5 Galectin Therapeutics Recent Developments
10.10 Galmed Pharmaceuticals
10.10.1 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
10.10.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
10.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.10.4 Galmed Pharmaceuticals Business Overview
10.10.5 Galmed Pharmaceuticals Recent Developments
10.11 Genfit
10.11.1 Genfit Nonalcoholic Steatohepatitis (NASH) Basic Information
10.11.2 Genfit Nonalcoholic Steatohepatitis (NASH) Product Overview
10.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.11.4 Genfit Business Overview
10.11.5 Genfit Recent Developments
10.12 Gilead
10.12.1 Gilead Nonalcoholic Steatohepatitis (NASH) Basic Information
10.12.2 Gilead Nonalcoholic Steatohepatitis (NASH) Product Overview
10.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Product Market Performance
10.12.4 Gilead Business Overview
10.12.5 Gilead Recent Developments
11 Nonalcoholic Steatohepatitis (NASH) Market Forecast by Region
11.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast
11.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
11.2.3 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Region
11.2.4 South America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Nonalcoholic Steatohepatitis (NASH) by Type (2025-2032)
12.1.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Nonalcoholic Steatohepatitis (NASH) by Type (2025-2032)
12.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Application (2025-2032)
12.2.1 Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) Forecast by Application
12.2.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Nonalcoholic Steatohepatitis (NASH) Market Size Comparison by Region (M USD)
Table 5. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Manufacturers (2019-2025)
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2022)
Table 10. Global Market Nonalcoholic Steatohepatitis (NASH) Average Price (USD/Unit) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Nonalcoholic Steatohepatitis (NASH) Sales Sites and Area Served
Table 12. Manufacturers Nonalcoholic Steatohepatitis (NASH) Product Type
Table 13. Global Nonalcoholic Steatohepatitis (NASH) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Nonalcoholic Steatohepatitis (NASH)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Nonalcoholic Steatohepatitis (NASH) Market Challenges
Table 22. Global Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 23. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 24. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2019-2025)
Table 25. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2019-2025)
Table 26. Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2019-2025)
Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Type (2019-2025)
Table 28. Global Nonalcoholic Steatohepatitis (NASH) Price (USD/Unit) by Type (2019-2025)
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application
Table 30. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application
Table 31. Global Nonalcoholic Steatohepatitis (NASH) Sales by Application (2019-2025) & (K Units)
Table 32. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2019-2025)
Table 33. Global Nonalcoholic Steatohepatitis (NASH) Sales by Application (2019-2025) & (M USD)
Table 34. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2019-2025)
Table 35. Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2019-2025)
Table 36. Global Nonalcoholic Steatohepatitis (NASH) Sales by Region (2019-2025) & (K Units)
Table 37. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region (2019-2025)
Table 38. North America Nonalcoholic Steatohepatitis (NASH) Sales by Country (2019-2025) & (K Units)
Table 39. Europe Nonalcoholic Steatohepatitis (NASH) Sales by Country (2019-2025) & (K Units)
Table 40. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales by Region (2019-2025) & (K Units)
Table 41. South America Nonalcoholic Steatohepatitis (NASH) Sales by Country (2019-2025) & (K Units)
Table 42. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales by Region (2019-2025) & (K Units)
Table 43. Global Nonalcoholic Steatohepatitis (NASH) Production (K Units) by Region (2019-2025)
Table 44. Global Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2019-2025)
Table 46. Global Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 47. North America Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 48. Europe Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 49. Japan Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 50. China Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 51. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 52. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 53. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
Table 56. AstraZeneca Recent Developments
Table 57. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 58. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 59. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 60. Arena Pharmaceuticals Business Overview
Table 61. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
Table 62. Arena Pharmaceuticals Recent Developments
Table 63. GSK Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 64. GSK Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 65. GSK Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 66. GSK Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
Table 67. GSK Business Overview
Table 68. GSK Recent Developments
Table 69. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 70. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 71. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 72. Novo Nordisk Business Overview
Table 73. Novo Nordisk Recent Developments
Table 74. Roche Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 75. Roche Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 76. Roche Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 77. Roche Business Overview
Table 78. Roche Recent Developments
Table 79. Vivus Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 80. Vivus Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 81. Vivus Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 82. Vivus Business Overview
Table 83. Vivus Recent Developments
Table 84. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 85. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 86. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 87. Arisaph Pharmaceuticals Business Overview
Table 88. Arisaph Pharmaceuticals Recent Developments
Table 89. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 90. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 91. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 92. Cempra Pharmaceuticals Business Overview
Table 93. Cempra Pharmaceuticals Recent Developments
Table 94. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 95. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 96. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 97. Galectin Therapeutics Business Overview
Table 98. Galectin Therapeutics Recent Developments
Table 99. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 100. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 101. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 102. Galmed Pharmaceuticals Business Overview
Table 103. Galmed Pharmaceuticals Recent Developments
Table 104. Genfit Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 105. Genfit Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 106. Genfit Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 107. Genfit Business Overview
Table 108. Genfit Recent Developments
Table 109. Gilead Nonalcoholic Steatohepatitis (NASH) Basic Information
Table 110. Gilead Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 111. Gilead Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 112. Gilead Business Overview
Table 113. Gilead Recent Developments
Table 114. Global Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Region (2025-2032) & (K Units)
Table 115. Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Region (2025-2032) & (M USD)
Table 116. North America Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Country (2025-2032) & (K Units)
Table 117. North America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country (2025-2032) & (M USD)
Table 118. Europe Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Country (2025-2032) & (K Units)
Table 119. Europe Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country (2025-2032) & (M USD)
Table 120. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Region (2025-2032) & (K Units)
Table 121. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Region (2025-2032) & (M USD)
Table 122. South America Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Country (2025-2032) & (K Units)
Table 123. South America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country (2025-2032) & (M USD)
Table 124. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2025-2032) & (Units)
Table 125. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country (2025-2032) & (M USD)
Table 126. Global Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Type (2025-2032) & (K Units)
Table 127. Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type (2025-2032) & (M USD)
Table 128. Global Nonalcoholic Steatohepatitis (NASH) Price Forecast by Type (2025-2032) & (USD/Unit)
Table 129. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) Forecast by Application (2025-2032)
Table 130. Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Nonalcoholic Steatohepatitis (NASH)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD), 2019-2032
Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) (2019-2032)
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Nonalcoholic Steatohepatitis (NASH) Market Size by Country (M USD)
Figure 11. Nonalcoholic Steatohepatitis (NASH) Sales Share by Manufacturers in 2023
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Manufacturers in 2023
Figure 13. Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Nonalcoholic Steatohepatitis (NASH) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type
Figure 18. Sales Market Share of Nonalcoholic Steatohepatitis (NASH) by Type (2019-2025)
Figure 19. Sales Market Share of Nonalcoholic Steatohepatitis (NASH) by Type in 2023
Figure 20. Market Size Share of Nonalcoholic Steatohepatitis (NASH) by Type (2019-2025)
Figure 21. Market Size Market Share of Nonalcoholic Steatohepatitis (NASH) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application
Figure 24. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2019-2025)
Figure 25. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application in 2023
Figure 26. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2019-2025)
Figure 27. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application in 2023
Figure 28. Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2019-2025)
Figure 29. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region (2019-2025)
Figure 30. North America Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 31. North America Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Country in 2023
Figure 32. U.S. Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 33. Canada Nonalcoholic Steatohepatitis (NASH) Sales (K Units) and Growth Rate (2019-2025)
Figure 34. Mexico Nonalcoholic Steatohepatitis (NASH) Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 36. Europe Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Country in 2023
Figure 37. Germany Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 38. France Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 39. U.K. Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 40. Italy Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 41. Russia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 42. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region in 2023
Figure 44. China Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 45. Japan Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 46. South Korea Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 47. India Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 48. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 49. South America Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (K Units)
Figure 50. South America Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Country in 2023
Figure 51. Brazil Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 52. Argentina Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 53. Columbia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 54. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 57. UAE Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 58. Egypt Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 59. Nigeria Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 60. South Africa Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2019-2025) & (K Units)
Figure 61. Global Nonalcoholic Steatohepatitis (NASH) Production Market Share by Region (2019-2025)
Figure 62. North America Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2019-2025)
Figure 63. Europe Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2019-2025)
Figure 64. Japan Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2019-2025)
Figure 65. China Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2019-2025)
Figure 66. Global Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Type (2025-2032)
Figure 70. Global Nonalcoholic Steatohepatitis (NASH) Sales Forecast by Application (2025-2032)
Figure 71. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Application (2025-2032)
